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Glucocorticoids, 11b-hydroxysteroid dehydrogenase, and fetal of hypertension, hyperlipidemia, insulin resistance, type
programming. Epidemiological studies in many distinct human 2 diabetes, and ischemic heart disease deaths in adult
populations have associated low weight or thinness at birth with life [1–13]. Classic adult lifestyle risk factors (smoking,a substantially increased risk of cardiovascular and metabolic
alcohol, obesity, social class) appear to be additive todisorders, including hypertension and insulin resistance/type 2
these early life effects [3]. Importantly, the relationshipsdiabetes, in adult life. The concept of fetal “programming” has
been advanced to explain this phenomenon. Prenatal glucocor- represent birthweights within the normal range, rather
ticoid therapy reduces birthweight, and steroids are known to than severe intrauterine growth retardation, multiple ba-
exert long-term organizational effects during specific “win-
bies, or very premature babies. Indeed, the smaller ofdows” of development. Therefore, we hypothesized that fetal
twins at birth apparently has the higher blood pressureoverexposure to endogenous glucocorticoids might underpin
the link between early life events and later disease. In rats, in later life [14]. Postnatal “catch-up” growth is also a
birthweight is reduced following prenatal exposure to the syn- risk factor for subsequent hypertension, ischemic heart
thetic glucocorticoid dexamethasone, which readily crosses the disease, and insulin resistance [3, 9, 14, 15], perhaps sug-
placenta, or to carbenoxolone, which inhibits 11b-hydroxyste-
gesting that smallness at birth due to environmental in-roid dehydrogenase type 2 (11b-HSD2), the physiological feto-
fluences restraining intrauterine growth are of impor-placental “barrier” to endogenous glucocorticoids. Although
the offspring regain the weight deficit by weaning, as adults they tance. The “early life” associations appear also to be
exhibit permanent hypertension, hyperglycemia, and increased important predictors of later disease. In Preston, a small
hypothalamic-pituitary-adrenal axis activity. Moreover, physi- baby with a large placenta had a relative risk of adultological variations in placental 11b-HSD2 activity near term
hypertension three times that of a large baby with acorrelate directly with fetal weight. In humans, 11b-HSD2 gene
mutations produce a low birthweight, and some studies show normal placenta [16]. In 22,000 American men, babies
reduced placental 11b-HSD2 activity in association with intra- born lighter than 5.5 pounds had a relative risk of adult
uterine growth retardation. Moreover, low birthweight babies hypertension of 1.26 and of type 2 diabetes of 1.75 com-
have higher plasma cortisol levels throughout adult life, indicat-
pared with babies of average birthweight. Similarly, theing that hypothalamic-pituitary-adrenal axis programming also
relative risk of hypertension in light normal babies wasoccurs in humans. The molecular mechanisms of glucocorticoid
programming are beginning to be unraveled and involve per- 1.43 in 71,000 female U.S. nurses [5, 6].
manent and tissue-specific changes in the expression of key
genes, notably of the glucocorticoid receptor itself. Thus, gluco-
corticoid programming may explain, in part, the association PROGRAMMING
between fetal events and subsequent disorders in adult life.
To explain these findings, the concept of early life
physiological “programming” has been proposed [3, 17,
18]. Such programming has been shown in a variety ofExtensive epidemiological studies suggest that factors
experimental model systems and reflects the action of aoperating in early life are important determinants of the
factor during a sensitive period or “window” of develop-risk of common and interassociated cardiovascular and
ment to exert organizational effects that persist throughmetabolic disorders of adult life. Data from several dis-
life. Perinatally, programming factors might produce ad-tinct populations in the Europe, Asia, Australia, and
aptations that optimize survival under conditions ofNorth America have shown that low birthweight or thin-
stress or deprivation; such responses might be detrimen-ness at birth strongly predicts the subsequent occurrence
tal when the adult environment is not as adverse as
“anticipated.” Of course, genetic and epigenetic factors
that restrain fetal growth and produce later disease mayKey words: placenta, fetal growth, glucocorticoid receptor, type 2 dia-
betes mellitus, hypertension. also explain these phenomena, and indeed, loci linked
to both low birthweight and adult disorders have beenÓ 2000 by the International Society of Nephrology
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reported [19, 20]. However, the data suggest that envi- GLUCOCORTICOID PROGRAMMING
ronmental effects occur, and these have been the main Crucially, prenatal glucocorticoid exposure produces
focus of mechanistic research. permanently elevated offspring blood pressure levels in
A major environmental factor advocated in explanation later life. Treatment of pregnant rats with modest doses
of fetal programming is maternal malnutrition. Indeed, of dexamethasone, a synthetic glucocorticoid used in
dietary restriction during pregnancy in rats, particularly obstetric practice, reduces birthweight and elevates
of protein, produces some reduction in birthweight and blood pressure in the adult offspring [49]. Even short-
permanent hypertension and hyperglycemia in the adult term glucocorticoid exposure in the last trimester in-
offspring [21–24], effects amplified by later obesity. How- creases blood pressure in adult life in rats [50]. These
ever, the mechanisms that mediate the effects of mater- effects are not related to persisting differences in off-
nal undernutrition on later disease in the offspring are spring weight, which normalizes by weaning. Last-trimes-
not fully understood, and any relevance in modern hu- ter administration of dexamethasone also “programs”
man populations is moot [25]. Even studies of people born permanent hyperglycemia and, particularly, hyperinsu-
during the extreme starvation of the siege of Leningrad linemia in the adult offspring [51]. In contrast, earlier
prenatal or postnatal exposure to dexamethasone, whilein World War II do not support any strong association
reducing fetal or infant growth, has no persisting effectsbetween maternal nutrition and offspring disorders [26].
on glucose homeostasis in adult life.
GLUCOCORTICOIDS AND PROGRAMMING
PHYSIOLOGICAL GLUCOCORTICOIDS ANDLong-term organizational effects are typically found
PLACENTAL 11b-HYDROXYSTEROIDwith hormones, particularly steroids. An example is the
DEHYDROGENASE TYPE 2action of androgens, which neonatally program the ex-
Although glucocorticoids are highly lipophilic and rap-pression hepatic steroid-metabolizing enzymes, the de-
idly cross the placenta, normally the fetus has much lowervelopment of sexually dimorphic structures in the brain
levels of physiological glucocorticoids than its motherand of sexual behavior [27, 28]. These effects can only
[52, 53]. This is achieved by placental 11b-hydroxysteroidbe exerted during a specific perinatal period, but then
dehydrogenase type 2 (11b-HSD2), which catalyzes thepersist throughout life, largely irrespective of any subse-
rapid metabolism of cortisol and corticosterone to inertquent sex steroid manipulations.
11-keto forms (cortisone, 11-dehydrocorticosterone)Physiological glucocorticoids (cortisol in humans, corti-
[54, 55]. This placental enzymic barrier ensures that most,costerone in rats and mice) are synthesized in the adrenal
but not all [56], maternal cortisol is inactivated so thatcortex. Several features of fetal glucocorticoid overexpo-
the majority of cortisol in the human fetal circulation atsure suggest a plausible role in the early life programming
term is derived from the fetal adrenals. Dexamethasone,of adult cardiovascular and metabolic disorders.
a poor substrate for 11b-HSD2, crosses the placenta
Exogenous glucocorticoids retard fetal growth in hu-
readily. The efficiency of placental 11b-HSD2 near term
mans and experimental animals, including nonhuman varies considerably in both rats and humans [49, 57]. It
primates [18, 29–32]. In humans, fetal cortisol levels are has therefore been hypothesized that relative deficiency
increased in intrauterine growth retardation, whether of placental 11b-HSD2, by allowing increased access of
idiopathic or caused by pre-eclampsia [33, 34]. maternal glucocorticoids to the fetus, may retard growth
Prenatal glucocorticoids alter the rate of maturation and program responses leading to later disease (Fig. 1)
of various organs such as the lung, heart, kidney, and [17]. Indeed, in rats, lower placental 11b-HSD activity
gut [reviewed in 18]. Some effects are transient, whereas and presumably greater fetal exposure to maternal glu-
others persist throughout life. Perinatal glucocorticoids cocorticoids are seen in the smallest fetuses with the
or stress program specific effects in the brain, notably largest placentas. Similar associations between birth-
the hypothalamic-pituitary-adrenal (HPA) axis and do- weight and placental 11b-HSD2 have been mooted in
paminergic motor systems [35–40]. Glucocorticoids also humans [57], although not all studies have confirmed
program the immune system [41] and the kidney [42, 43]. this observation [58]. However, deleterious mutations of
Glucocorticoid receptors (GRs) are highly expressed the 11b-HSD2 gene in humans associate with very low
in most, if not all, fetal tissues from midgestation or birthweight [59]. Furthermore, biochemical markers of
earlier [44, 45], as well as in placenta and fetal mem- fetal exposure to glucocorticoids correlate with placental
branes. 11b-HSD2 function at term [60]. Mechanistic studies in
Glucocorticoids increase blood pressure and blood pregnant rats with the 11b-HSD carbenoxolone have
glucose levels in adults [46]. Cortisol also elevates fetal shown similar effects to dexamethasone, with reduced
blood pressure when infused directly in utero in sheep birthweight and hypertension and hyperglycemia in the
adult offspring (Fig. 2) [61, 62]. These effects of carben-[47] and at birth in humans and sheep [32, 48].
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Fig. 1. Placental 11b-hydroxysteroid dehy-
drogenase type 2 (11b-HSD2) acts as a “bar-
rier” to active glucocorticoids (cortisol, s) in
the maternal circulation, converting these to
inert 11 keto forms (cortisone, m). Lower ac-
tivity of placental 11b-HSD2 (right panel)
allows greater passage of cortisol to the fetal
circulation, which may underlie deleterious
short-and long-term effects, including intra-
uterine growth retardation and “program-
ming” of responses.
Fig. 2. Prenatal carbenoxolone (CBX) treat-
ment reduces birthweight ( ) and programs
permanent hypertension and hyperglycemia
(fasting and post-prandial) in the adult off-
spring compared with control offspring (Con;
j) of vehicle-treated pregnancies. Adult off-
spring were given oral glucose after 0 minutes.
Symbols are: (d, solid line) CBX in utero;
(d, dashed line) control.
oxolone are apparently independent of changes in mater- nancy selectively attenuates 11b-HSD2, but not other
enzymes in the placenta [63], and leads to hypertension,nal blood pressure or electrolytes, but require maternal
glucocorticoids (that is, they are not seen in the offspring hyperglycemia, and so forth. Thus, glucocorticoid expo-
sure may be one of a limited series of common mecha-of adrenalectomized pregnant rats given carbenoxolone).
Intriguingly, dietary protein restriction during rat preg- nisms linking maternal environmental factors with fetal
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growth and programming. Indeed, in the maternal pro- corticosterone, suggesting the increased hepatic GR ex-
pression is of functional importance [51]. Of course, thistein restriction model, offspring hypertension can be pre-
vented by giving the pregnant dam (and her offspring) begs the question of what happens to plasma corticoste-
rone levels in such models.glucocorticoid synthesis inhibitors, and can be recreated
by concurrent “replacement” of corticosterone, at least Prenatal dexamethasone permanently attenuates GR
(and mineralocorticoid receptor) gene expression in thein female offspring [64]. A note of caution is necessary,
however, since 11b-HSD2 null mice have a normal adult rat hippocampus, a key region responsible for me-
diating glucocorticoid negative feedback on the HPAbirthweight [65]. However, in mice, there is early “shut-
off” of 11b-HSD-2 gene expression in the placenta dur- axis. This may well underpin the documented increases
in basal plasma corticosterone levels in adulthood bying midgestation [66], whereas birthweight predomi-
nantly reflects growth late in gestation. Thus, in this reducing sensitivity to glucocorticoid feedback [50]. Of
course, elevated glucocorticoid levels might contributespecies, the “barrier” may not exist during the phase of
maximal growth. In contrast, the activity of 11b-HSD2 directly to hypertension and hyperglycemia [49]. The
reader will have noted that GR transcript levels are ele-in rat placenta is maintained until later in gestation [49],
and in many other mammals, including humans, placen- vated in the liver, but reduced in the hippocampus in the
tal 11b-HSD2 activity is fully maintained or even in- prenatal dexamethasone model. The molecular mecha-
creases toward term [57, 67]. Thus, there are clear species nisms are under current study, but may reflect differen-
differences in the ontogeny of 11b-HSD-2 expression in tial promoter usage by the GR gene in each tissue.
the placenta, hindering the confidence in extrapolating Crucially, the rat models have allowed further predic-
data from results with 11b-HSD inhibition/disruption in tions to be made in humans. Indeed, low birthweight also
rodent species (particularly the mouse) to humans. correlates with increased adult cortisol levels in humans
[74]. Thus, the prenatal glucocorticoid exposure models
Sites of glucocorticoid action have reproduced and indeed extended our understand-
Glucocorticoids or 11b-HSD inhibitors administered ing of the fetal origins phenomena. Whether glucocorti-
during pregnancy might affect the fetus, the placenta, coids and feto-placental 11b-HSD2 deficiency are com-
and/or the mother. Each is plausible [reviewed in 18], mon or exceptional mechanisms of fetal programming in
although direct feto-placental effects seem most likely humans remains a key question for future investigation.
[61, 62]. Nevertheless, maternal hypertension is linked
to fetal high blood pressure and hyperglycemia [68, 69]. ACKNOWLEDGMENTS
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